About Us

About Us

Meaningful, innovative and evidence-based analysis to
help inform key decision making.

Our goal is to be the business intelligence partner of choice for companies in the healthcare arena looking for meaningful, innovative and evidence-based analysis to inform their key decision making. As a trusted and reliable partner, GBI Research helps clients to better understand their business environment, compete successfully within it, and to achieve growth.

At GBI Research, we leverage extensive proprietary databases and employ novel data interrogation methodologies to generate new and meaningful analyses and insights.

Our content and coverage are informed by close collaboration with a global network of domain-specific external partners; this allows us to deliver novel, thought-provoking and idea-generating insights that clients would normally struggle to access.

Our in-house team of researchers and analysts – typically with MBAs, PhDs and MScs, as well as considerable healthcare industry experience is located across the UK, US and Asia Pacific. The team provides expert and insightful commentary to support evidence-based analyses of established and emerging markets.

More than 2,000 clients benefit from the GBI Research product set. Reports are available to purchase as individual research reports or via our online subscription platform, request a demo today to see how it works.

Analyst Views

28 Nov 16
Repurposing Type 2 Diabetes Mellitus Drugs for Alzheimer’s ....
In this Analyst View, Fiona Chisholm, Analyst for GBI Research, discusses the potential f.....
Read post
21 Nov 16
Urological Cancer Treatment Landscape to be Transformed by ....
In this Analyst View, Adam Bradbury, Associate Analyst for GBI Research, discuses current.....
Read post

White Papers

22 Nov 16
An Exploration of Novel and Repositioned Calcium Transport ....
This whitepaper discusses the increasing interest in using repositioned calcium transport....
Read post
14 Nov 16
The Emerging Field of Cannabinoid-Based Products....
This white paper discusses the current commercial landscape for cannabinoid-based product....
Read post

Press Releases

15 Feb 17
Immunology attracting high level of investment as companies....
With a total of 2,145 products currently in development, the immunology market is experie.....
Read post
14 Feb 17
Roche to gain most as Biogen remains leader in neurodegener....
Roche will be the biggest mover in the neurodegenerative drugs space over the next five y.....
Read post